Active, not recruitingPhase 1NCT04661384

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

Studying Ependymoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
City of Hope Medical Center
Principal Investigator
Lisa A Feldman
City of Hope Medical Center
Intervention
IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes(biological)
Enrollment
10 enrolled
Eligibility
18 years · All sexes
Timeline
20212027

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04661384 on ClinicalTrials.gov

Other trials for Ependymoma

Additional recruiting or active studies for the same condition.

See all trials for Ependymoma

← Back to all trials